Evidence map›Paper›PMID 40536045›Full record

ReviewChemistry, an Asian journal2025

Advances in Small Molecule Inhibitors Targeting the Bacterial Lipoprotein Transport System (Lol) in Gram-Negative Bacteria.

Saemee Song, Su Yong Shim

Abstract readReview
In one paragraph

Review in Chemistry, an Asian journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Mechanistic Evaluation of LolA andInternational journal of microbiology · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Saemee SongInfectious Diseases Therapeutic Research Center, Division of Medicinal Chemistry and Pharmacology, Korea Research Institute of Chemical Technology (KRICT), Daejeon, 34114, Republic of Korea.
Su Yong ShimInfectious Diseases Therapeutic Research Center, Division of Medicinal Chemistry and Pharmacology, Korea, Research Institute of Chemical Technology (KRICT), KRICT school, University of Science and Technology, Daejeon, 34114, Republic of Korea.ORCID 0000-0003-4385-0040

Funding

Institutional Research Program of the KRICT KK2532-10
6 · The paper itself

Abstract

The escalating threat of antimicrobial resistance (AMR) necessitates the urgent development of novel antibiotics, particularly those against multidrug-resistant gram-negative bacteria. These pathogens possess formidable structural defenses, including an impermeable outer membrane (OM) and robust efflux pumps, which hinder antibiotic efficacy. A promising therapeutic target is the lipoprotein transport system (Lol), which is essential for bacterial viability. The LolABCDE complex ensures the precise localization of lipoproteins, which is crucial for maintaining outer membrane integrity and cell survival. Disruption of this system results in severe structural and functional defects that lead to bacterial cell death. This review explores the recent advances in small-molecule inhibitors targeting the Lol system and examines the mechanisms of LolABCDE function, along with the structural and biochemical characteristics of its components. We also summarize the progress made in the discovery and optimization of inhibitors, including their modes of action, resistance mechanisms, and therapeutic potential. Despite significant progress, challenges, such as limited drug permeability and emerging resistance, continue to hinder therapeutic success. Overcoming these challenges necessitates strategies to enhance inhibitor selectivity and bypass the intrinsic defense mechanisms of gram-negative bacteria. This review aims to provide insights into the potential of targeting the Lol system as a novel strategy for combating antimicrobial resistance and developing effective therapies against gram-negative bacterial infections.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsGram-Negative BacteriaLipoproteinsSmall Molecule LibrariesHumansAnti-Bacterial AgentsBacterial ProteinsLipoproteinsSmall Molecule LibrariesAntibioticsGram‐negative bacteriaLipoprotein transport systemLolABCDESmall‐molecule inhibitors

Identifiers

PMID40536045
PMCPMC12447863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.